1. Product Overview
1.1. Market Definition
1.2.
Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for
Study
1.2.3. Key Market
Segmentations
2. Research Methodology
2.1.
Objective of the Study
2.2.
Baseline Methodology
2.3.
Key Industry Partners
2.4.
Major Association and Secondary Sources
2.5.
Forecasting Methodology
2.6.
Data Triangulation & Validation
2.7.
Assumptions and Limitations
3. Executive Summary
3.1.
Overview of the Market
3.2.
Overview of Key Market Segmentations
3.3.
Overview of Key Market Players
3.4.
Overview of Key Regions/Countries
3.5.
Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Clinical Trial
Analysis
5.1.
Ongoing Clinical Trials
5.2.
Completed Clinical Trials
5.3.
Terminated Clinical Trials
5.4.
Breakdown of Pipeline, By Development Phase
5.5.
Breakdown of Pipeline, By Status
5.6.
Breakdown of Pipeline, By Study Type
5.7.
Breakdown of Pipeline, By Region
5.8.
Clinical Trials Heat Map
6. Global Cell &
Gene Therapy Drug Delivery Devices Market Outlook
6.1.
Market Size & Forecast
6.1.1.
By Value
6.2.
Market Share & Forecast
6.2.1.
By Type (Subretinal Injection Cannula, Extension Tube,
Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags)
6.2.2.
By Commercialized Drugs (Luxturna, Kymriah, Yescarta,
Zolgensma, Provenge, Strimvelis)
6.2.3.
By Route of Administration (Oral, Intravenous, Ocular,
Transdermal, Others)
6.2.4.
By Method (In Vitro v/s Ex Vivo)
6.2.5.
By Company (2022)
6.2.6. By
Region
6.3.
Market Map
6.3.1.
By Type
6.3.2.
By Commercialized Drugs
6.3.3.
By Route of Administration
6.3.4.
By Method
6.3.5.
By Region
7. Asia-Pacific Cell
& Gene Therapy Drug Delivery Devices Market Outlook
7.1.
Market Size & Forecast
7.1.1.
By Value
7.2.
Market Share & Forecast
7.2.1.
By Type (Subretinal Injection Cannula, Extension Tube,
Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags)
7.2.2.
By Commercialized Drugs (Luxturna, Kymriah, Yescarta,
Zolgensma, Provenge, Strimvelis)
7.2.3.
By Route of Administration (Oral, Intravenous, Ocular,
Transdermal, Others)
7.2.4.
By Method (In Vitro v/s Ex Vivo)
7.2.5.
By Country
7.3.
Asia-Pacific: Country Analysis
7.3.1.
China Cell & Gene Therapy Drug Delivery Devices
Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Type
7.3.1.2.2.
By Commercialized Drugs
7.3.1.2.3.
By Route of Administration
7.3.1.2.4.
By Method
7.3.2.
India Cell & Gene Therapy Drug Delivery Devices
Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Type
7.3.2.2.2.
By Commercialized Drugs
7.3.2.2.3.
By Route of Administration
7.3.2.2.4.
By Method
7.3.3.
South Korea Cell & Gene Therapy Drug Delivery Devices
Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Type
7.3.3.2.2.
By Commercialized Drugs
7.3.3.2.3.
By Route of Administration
7.3.3.2.4.
By Method
7.3.4.
Japan Cell & Gene Therapy Drug Delivery Devices
Market Outlook
7.3.4.1.
Market Size & Forecast
7.3.4.1.1.
By Value
7.3.4.2.
Market Share & Forecast
7.3.4.2.1.
By Type
7.3.4.2.2.
By Commercialized Drugs
7.3.4.2.3.
By Route of Administration
7.3.4.2.4.
By Method
7.3.5.
Australia Cell & Gene Therapy Drug Delivery Devices
Market Outlook
7.3.5.1.
Market Size & Forecast
7.3.5.1.1.
By Value
7.3.5.2.
Market Share & Forecast
7.3.5.2.1.
By Type
7.3.5.2.2.
By Commercialized Drugs
7.3.5.2.3.
By Route of Administration
7.3.5.2.4.
By Method
8. Europe Cell &
Gene Therapy Drug Delivery Devices Market Outlook
8.1.
Market Size & Forecast
8.1.1.
By Value
8.2.
Market Share & Forecast
8.2.1.
By Type (Subretinal Injection Cannula, Extension Tube,
Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags)
8.2.2.
By Commercialized Drugs (Luxturna, Kymriah, Yescarta,
Zolgensma, Provenge, Strimvelis)
8.2.3.
By Route of Administration (Oral, Intravenous, Ocular,
Transdermal, Others)
8.2.4.
By Method (In Vitro v/s Ex Vivo)
8.2.5.
By Country
8.3.
Europe: Country Analysis
8.3.1.
France Cell & Gene Therapy Drug Delivery Devices
Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Type
8.3.1.2.2.
By Commercialized Drugs
8.3.1.2.3.
By Route of Administration
8.3.1.2.4.
By Method
8.3.2.
Germany Cell & Gene Therapy Drug Delivery Devices
Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Type
8.3.2.2.2.
By Commercialized Drugs
8.3.2.2.3.
By Route of Administration
8.3.2.2.4.
By Method
8.3.3.
United Kingdom Cell & Gene Therapy Drug Delivery
Devices Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Type
8.3.3.2.2.
By Commercialized Drugs
8.3.3.2.3.
By Route of Administration
8.3.3.2.4.
By Method
8.3.4.
Italy Cell & Gene Therapy Drug Delivery Devices
Market Outlook
8.3.4.1.
Market Size & Forecast
8.3.4.1.1.
By Value
8.3.4.2.
Market Share & Forecast
8.3.4.2.1.
By Type
8.3.4.2.2.
By Commercialized Drugs
8.3.4.2.3.
By Route of Administration
8.3.4.2.4.
By Method
8.3.5.
Spain Cell & Gene Therapy Drug Delivery Devices
Market Outlook
8.3.5.1.
Market Size & Forecast
8.3.5.1.1.
By Value
8.3.5.2.
Market Share & Forecast
8.3.5.2.1.
By Type
8.3.5.2.2.
By Commercialized Drugs
8.3.5.2.3.
By Route of Administration
8.3.5.2.4.
By Method
9. North America Cell
& Gene Therapy Drug Delivery Devices Market Outlook
9.1.
Market Size & Forecast
9.1.1.
By Value
9.2.
Market Share & Forecast
9.2.1.
By Type (Subretinal Injection Cannula, Extension Tube,
Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags)
9.2.2.
By Commercialized Drugs (Luxturna, Kymriah, Yescarta,
Zolgensma, Provenge, Strimvelis)
9.2.3.
By Route of Administration (Oral, Intravenous, Ocular,
Transdermal, Others)
9.2.4.
By Method (In Vitro v/s Ex Vivo)
9.2.5.
By Country
9.3.
North America: Country Analysis
9.3.1.
United States Cell & Gene Therapy Drug Delivery
Devices Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Type
9.3.1.2.2.
By Commercialized Drugs
9.3.1.2.3.
By Route of Administration
9.3.1.2.4.
By Method
9.3.2.
Mexico Cell & Gene Therapy Drug Delivery Devices
Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Type
9.3.2.2.2.
By Commercialized Drugs
9.3.2.2.3.
By Route of Administration
9.3.2.2.4.
By Method
9.3.3.
Canada Cell & Gene Therapy Drug Delivery Devices
Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Type
9.3.3.2.2.
By Commercialized Drugs
9.3.3.2.3.
By Route of Administration
9.3.3.2.4.
By Method
10. South America Cell
& Gene Therapy Drug Delivery Devices Market Outlook
10.1.
Market Size & Forecast
10.1.1.
By Value
10.2.
Market Share & Forecast
10.2.1.
By Type (Subretinal Injection Cannula, Extension Tube,
Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags)
10.2.2.
By Commercialized Drugs (Luxturna, Kymriah, Yescarta,
Zolgensma, Provenge, Strimvelis)
10.2.3.
By Route of Administration (Oral, Intravenous, Ocular,
Transdermal, Others)
10.2.4.
By Method (In Vitro v/s Ex Vivo)
10.2.5.
By Country
10.3.
South America: Country Analysis
10.3.1.
Brazil Cell & Gene Therapy Drug Delivery Devices
Market Outlook
10.3.1.1.
Market Size & Forecast
10.3.1.1.1.
By Value
10.3.1.2.
Market Share & Forecast
10.3.1.2.1.
By Type
10.3.1.2.2.
By Commercialized Drugs
10.3.1.2.3.
By Route of Administration
10.3.1.2.4.
By Method
10.3.2.
Argentina Cell & Gene Therapy Drug Delivery Devices
Market Outlook
10.3.2.1.
Market Size & Forecast
10.3.2.1.1.
By Value
10.3.2.2.
Market Share & Forecast
10.3.2.2.1.
By Type
10.3.2.2.2.
By Commercialized Drugs
10.3.2.2.3.
By Route of Administration
10.3.2.2.4.
By Method
10.3.3.
Colombia Cell & Gene Therapy Drug Delivery Devices
Market Outlook
10.3.3.1.
Market Size & Forecast
10.3.3.1.1.
By Value
10.3.3.2.
Market Share & Forecast
10.3.3.2.1.
By Type
10.3.3.2.2.
By Commercialized Drugs
10.3.3.2.3.
By Route of Administration
10.3.3.2.4.
By Method
11. Middle East and
Africa Cell & Gene Therapy Drug Delivery Devices Market Outlook
11.1.
Market Size & Forecast
11.1.1.
By Value
11.2.
Market Share & Forecast
11.2.1.
By Type (Subretinal Injection Cannula, Extension Tube,
Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags)
11.2.2.
By Commercialized Drugs (Luxturna, Kymriah, Yescarta,
Zolgensma, Provenge, Strimvelis)
11.2.3.
By Route of Administration (Oral, Intravenous, Ocular,
Transdermal, Others)
11.2.4.
By Method (In Vitro v/s Ex Vivo)
11.2.5.
By Country
11.3.
MEA: Country Analysis
11.3.1.
South Africa Cell & Gene Therapy Drug Delivery
Devices Market Outlook
11.3.1.1.
Market Size & Forecast
11.3.1.1.1.
By Value
11.3.1.2.
Market Share & Forecast
11.3.1.2.1.
By Type
11.3.1.2.2.
By Commercialized Drugs
11.3.1.2.3.
By Route of Administration
11.3.1.2.4.
By Method
11.3.2.
Saudi Arabia Cell & Gene Therapy Drug Delivery
Devices Market Outlook
11.3.2.1.
Market Size & Forecast
11.3.2.1.1.
By Value
11.3.2.2.
Market Share & Forecast
11.3.2.2.1.
By Type
11.3.2.2.2.
By Commercialized Drugs
11.3.2.2.3.
By Route of Administration
11.3.2.2.4.
By Method
11.3.3.
UAE Cell & Gene Therapy Drug Delivery Devices
Market Outlook
11.3.3.1.
Market Size & Forecast
11.3.3.1.1.
By Value
11.3.3.2.
Market Share & Forecast
11.3.3.2.1.
By Type
11.3.3.2.2.
By Commercialized Drugs
11.3.3.2.3.
By Route of Administration
11.3.3.2.4.
By Method
12. Market Dynamics
12.1.
Drivers
12.2.
Challenges
13. Market Trends &
Developments
13.1.
Recent Developments
13.2.
Mergers & Acquisitions
13.3.
Product Launches
14. Competitive
Landscape
14.1.
Business Overview
14.2.
Company Snapshot
14.3.
Products & Services
14.4.
Financials (As Reported)
14.5.
Recent Developments
14.6.
SWOT Analysis
14.6.1.
Becton, Dickinson, and
Company
14.6.2.
Novartis AG
14.6.3.
Amgen Inc.
14.6.4.
Kite Pharma, Inc.
14.6.5.
Pfizer, Inc.
14.6.6.
Bausch & Lomb
Incorporated
14.6.7.
Bluebird bio, Inc.
14.6.8.
Castle Creek
Biosciences, Inc (Fibrocell Technologies, Inc.)
14.6.9.
Dendreon
Pharmaceuticals LLC.
14.6.10.
Helixmith Co., Ltd
(ViroMed Co., Ltd)
Strategic Recommendations